Common bile duct disorder

Summary

Common bile duct disorder (MONDO:0002886) is a disease and 10 clinical trials. Top therapeutic interventions include diclofenac. A subtype of bile duct disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	common bile duct disorder
Mondo ID	MONDO:0002886
MeSH	D003137
DOID	DOID:4137
UMLS	C0009440
MedGen	3545
Anatomy (UBERON)	UBERON:0001174
Is cancer (heuristic)	no

Also known as: common bile duct disease · common bile duct disease or disorder · disease of common bile duct · disease or disorder of common bile duct · disorder of common bile duct

Disease family

This is a subtype of bile duct disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile duct disorder › common bile duct disorder

Related subtypes (6): perforation of bile duct, cholestasis, non-neoplastic bile duct disorder, bile duct cyst, bile duct neoplasm, fibrosis of bile duct

Subtypes (3): biliary dyskinesia, choledocholithiasis, common bile duct neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03595150	PHASE2/PHASE3	NOT_YET_RECRUITING	Diclofenac for Prevention of Post-ERC Pancreatitis
NCT02967926	PHASE3	COMPLETED	Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy
NCT05755594	Not specified	NOT_YET_RECRUITING	A Prospective Study on the Safety and Efficacy of Robot-assisted Pancreaticoduodenectomy
NCT05755607	Not specified	NOT_YET_RECRUITING	A Multicenter Prospective Randomized Controlled Study of RPD Versus LPD
NCT00840138	Not specified	UNKNOWN	A Comparison of Bile Duct Injuries Following Open Cholecystectomy Versus Laparoscopic Cholecystectomy
NCT02596646	Not specified	TERMINATED	Early Precut in Difficult Biliary Cannulation
NCT03190343	Not specified	UNKNOWN	Assessment of Cholangio-pancreatoscopy for the Diagnosis and the Treatment of Biliary and Pancreatic Diseases
NCT04503200	Not specified	UNKNOWN	Double Guidewire Technique Versus Transpancreatic Precut in Patients With Repetitive Unintentional Cannulation of the Pancreatic Duct.
NCT05660915	Not specified	UNKNOWN	A Prospective Clinical Study Using an Artery-first Intermediate Approach in Robot-assisted Pancreaticoduodenectomy
NCT05945797	Not specified	COMPLETED	Effects of Dexamethasone on Common Bile Duct Cannulation Time

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DICLOFENAC	4	1